<DOC>
	<DOC>NCT01785901</DOC>
	<brief_summary>This is a multi-centre, cross-sectional study planned to be conducted in China. The study aims to observe about 1500 asthma patients who have already received budesonide/formoterol combination treatment by physicians' determination and whose medications are aligned with the package insert of budesonide/formoterol approved in China.</brief_summary>
	<brief_title>The Asthma Control Rate Achieved by Budesonide/Formoterol in Clinical Practice in China</brief_title>
	<detailed_description>The asthma control rate achieved by budesonide/formoterol in clinical practice in China.</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>1. Clinical diagnosis of asthma at least 6 months; 2. Prescribed with budesonide/formoterol treatment at least 3 months before enrolled; 3. Has used the same maintenance dose of budesonide/formoterol for at least 4 weeks before enrolled. 1. Participation in any clinical study within 3 months; 2. Have COPD history/suspicious COPD; 3. â‰¥ 10 pack years of smoking history 4. Used any other asthma maintenance medication accompanied with budesonide/formoterol within 3 months before enrolled 5. With asthma exacerbation (defined as asthma symptom deterioration resulting oral/rectal/parenteral GCS medication or emergency room treatment or hospitalisation) within 4 weeks before enrolled</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>asthma</keyword>
	<keyword>control rate</keyword>
	<keyword>budesonide/formoterol</keyword>
	<keyword>Non-Interventional study</keyword>
</DOC>